insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.

Cancer cell 2026 Vol.44(2) p. 355-365.e3

Fan L, Zhang WJ, Li HP, Zeng XH, Teng YE, Gong Y, Jin X, Zhao S, Sun T, Chen WY, Wang SS, Yang J, Zhuang ZG, Ni SJ, He ZX, Fu DY, Song CG, Lv Z, Liang QN, Yu BH, Shi J, Wang N, Liang XR, Zhang NN, Wang Y, Ji P, Liu XY, Chen L, He M, Liu Y, Sui XY, Ma LX, Zhu XZ, Yang F, Ge LP, Wu SY, Wu J, Yu KD, Liu GY, Hu X, Shen Y, Pang Z, Wang JF, Liang F, Yang WT, Wang ZH, Jiang YZ, Shao ZM

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

We report the results of LINUX (NCT05594095), a multicenter, randomized, controlled phase II platform trial aiming to identify effective precision treatments for hormone receptor-positive/human epider

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 70

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Fan L, Zhang WJ, et al. (2026). Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.. Cancer cell, 44(2), 355-365.e3. https://doi.org/10.1016/j.ccell.2025.11.003
MLA Fan L, et al.. "Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.." Cancer cell, vol. 44, no. 2, 2026, pp. 355-365.e3.
PMID 41349543
DOI 10.1016/j.ccell.2025.11.003

Abstract

We report the results of LINUX (NCT05594095), a multicenter, randomized, controlled phase II platform trial aiming to identify effective precision treatments for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer after resistance to cyclin-dependent kinase 4/6 inhibitor. A total of 105 patients were categorized into four similarity network fusion (SNF) subtypes by artificial intelligence-assisted classification and randomly assigned to receive subtyping-based precision therapy (N = 70) or treatment of physician's choice (N = 35). Results demonstrate superior primary endpoint of objective response rates in the subtyping-based groups compared to controls: 10% versus 0% for SNF1, 65% versus 30% for SNF2, 40% versus 30% for SNF3, and 70% versus 20% for SNF4. Grade 3-4 treatment-related adverse events occurred in 37% of both groups. These findings highlight the clinical benefits of subtyping-based precision therapies, particularly for SNF2 and SNF4 subtypes, warranting further validation in phase III trials.

MeSH Terms

Humans; Breast Neoplasms; Female; Erb-b2 Receptor Tyrosine Kinases; Artificial Intelligence; Precision Medicine; Middle Aged; Adult; Receptors, Estrogen; Receptors, Progesterone; Aged; Treatment Outcome; Protein Kinase Inhibitors

같은 제1저자의 인용 많은 논문 (5)